Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

NCT04341077 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-04-10

No results posted yet for this study

Summary

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Conditions

  • Healthy Adult Male and Female Volunteers

Interventions

DRUG

SHR3162

A single oral dose of fluzoparib on Day 1

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2020-04-20
Completion
2020-10-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341077 on ClinicalTrials.gov